Lancet.Apr6;():-.doi:10./S-(18)-5.EpubMar8.
Veverimerversusplaceboinpatientswithmetabolicacidosisassociatedwithchronickidneydisease:amulticentre,randomised,double-blind,controlled,phase3trial.WessonDE1,MathurV2,TangriN3,StasivY4,ParsellD4,LiE5,KlaernerG4,BushinskyDA6.
AuthorinformationAbstractBACKGROUND:Patientswithadvancedchronickidneydiseaselosethecapacitytofullyexcreteendogenousacid,resultinginchronicmetabolicacidosisthatincreasestheriskofdiseaseprogressionandcausesmusclecatabolismandboneresorption.Veverimer,anon-absorbed,counterion-free,polymericdrug,selectivelybindsandremoveshydrochloricacidfromthegastrointestinallumen,unlikecurrentoralsodiumbicarbonatetherapyformetabolicacidosisthatonlyneutralisesaccumulatedacid.Weassessedtheefficacyandsafetyofveverimerasatreatmentformetabolicacidosisinpatientswithchronickidneydisease.
METHODS:Wedidamulticentre,parallel,randomised,double-blind,placebo-controlledstudyat37sites(hospitalsandspecialtyclinics)inBulgaria,Croatia,Georgia,Hungary,Serbia,Slovenia,Ukraine,andtheUSA.Eligibleparticipantswerepatientsaged18-85yearswithnon-dialysis-dependentchronickidneydisease(estimatedglomerularfiltrationrateof20-40mL/minper1·73m2)andmetabolicacidosis(serumbicarbonateconcentrationof12-20mmol/L).Patientswererandomlyassigned(4:3)toveverimer6g/dayorplacebofor12weekswhiletheyconsumedtheirtypicaldiet.Bothdrugsweretakenasoralsuspensionsinwaterwithlunch.Randomisationwasdonebystudysitepersonnelwitha白癜风诊疗体系白癜风治好需要多少钱
